Patients with early stage lung cancer live longer when they receive a lobectomy rather than a less extensive operation or radiation treatment, according to a study published in The Annals of Thoracic Surgery.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.Â
